Platelet-monocyte aggregates: molecular mediators of thromboinflammation
Platelets, key facilitators of primary hemostasis and thrombosis, have emerged as crucial cellular mediators of innate immunity and inflammation. Exemplified by their ability to alter the phenotype and function of monocytes, activated platelets bind to circulating monocytes to form monocyte-platelet...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-05-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2023.960398/full |
| _version_ | 1797826817391853568 |
|---|---|
| author | Christina C. Rolling Christina C. Rolling Tessa J. Barrett Jeffrey S. Berger |
| author_facet | Christina C. Rolling Christina C. Rolling Tessa J. Barrett Jeffrey S. Berger |
| author_sort | Christina C. Rolling |
| collection | DOAJ |
| description | Platelets, key facilitators of primary hemostasis and thrombosis, have emerged as crucial cellular mediators of innate immunity and inflammation. Exemplified by their ability to alter the phenotype and function of monocytes, activated platelets bind to circulating monocytes to form monocyte-platelet aggregates (MPA). The platelet-monocyte axis has emerged as a key mechanism connecting thrombosis and inflammation. MPA are elevated across the spectrum of inflammatory and autoimmune disorders, including cardiovascular disease, systemic lupus erythematosus (SLE), and COVID-19, and are positively associated with disease severity. These clinical disorders are all characterized by an increased risk of thromboembolic complications. Intriguingly, monocytes in contact with platelets become proinflammatory and procoagulant, highlighting that this interaction is a central element of thromboinflammation. |
| first_indexed | 2024-04-09T12:38:19Z |
| format | Article |
| id | doaj.art-220de8b9fdbf46c79d661862b1fb2edb |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-04-09T12:38:19Z |
| publishDate | 2023-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-220de8b9fdbf46c79d661862b1fb2edb2023-05-15T05:06:07ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2023-05-011010.3389/fcvm.2023.960398960398Platelet-monocyte aggregates: molecular mediators of thromboinflammationChristina C. Rolling0Christina C. Rolling1Tessa J. Barrett2Jeffrey S. Berger3Department of Medicine, New York University Grossman School of Medicine, New York, NY, United StatesDepartment of Oncology and Hematology, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyDepartment of Medicine, New York University Grossman School of Medicine, New York, NY, United StatesDepartment of Medicine, New York University Grossman School of Medicine, New York, NY, United StatesPlatelets, key facilitators of primary hemostasis and thrombosis, have emerged as crucial cellular mediators of innate immunity and inflammation. Exemplified by their ability to alter the phenotype and function of monocytes, activated platelets bind to circulating monocytes to form monocyte-platelet aggregates (MPA). The platelet-monocyte axis has emerged as a key mechanism connecting thrombosis and inflammation. MPA are elevated across the spectrum of inflammatory and autoimmune disorders, including cardiovascular disease, systemic lupus erythematosus (SLE), and COVID-19, and are positively associated with disease severity. These clinical disorders are all characterized by an increased risk of thromboembolic complications. Intriguingly, monocytes in contact with platelets become proinflammatory and procoagulant, highlighting that this interaction is a central element of thromboinflammation.https://www.frontiersin.org/articles/10.3389/fcvm.2023.960398/fullmonocyte-platelet aggregatesthromboinflammationantiplatelet therapyP2Y12 inhibitorinflammatory diseasesatherosclerosis |
| spellingShingle | Christina C. Rolling Christina C. Rolling Tessa J. Barrett Jeffrey S. Berger Platelet-monocyte aggregates: molecular mediators of thromboinflammation Frontiers in Cardiovascular Medicine monocyte-platelet aggregates thromboinflammation antiplatelet therapy P2Y12 inhibitor inflammatory diseases atherosclerosis |
| title | Platelet-monocyte aggregates: molecular mediators of thromboinflammation |
| title_full | Platelet-monocyte aggregates: molecular mediators of thromboinflammation |
| title_fullStr | Platelet-monocyte aggregates: molecular mediators of thromboinflammation |
| title_full_unstemmed | Platelet-monocyte aggregates: molecular mediators of thromboinflammation |
| title_short | Platelet-monocyte aggregates: molecular mediators of thromboinflammation |
| title_sort | platelet monocyte aggregates molecular mediators of thromboinflammation |
| topic | monocyte-platelet aggregates thromboinflammation antiplatelet therapy P2Y12 inhibitor inflammatory diseases atherosclerosis |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2023.960398/full |
| work_keys_str_mv | AT christinacrolling plateletmonocyteaggregatesmolecularmediatorsofthromboinflammation AT christinacrolling plateletmonocyteaggregatesmolecularmediatorsofthromboinflammation AT tessajbarrett plateletmonocyteaggregatesmolecularmediatorsofthromboinflammation AT jeffreysberger plateletmonocyteaggregatesmolecularmediatorsofthromboinflammation |